2024-05-08 06:55:36 ET
Summary
- Ascendis Pharma is expected to achieve cash flow break even by the end of 2024, driven by its core franchise of medicines for rare endocrinology conditions.
- The company's approved drug, Skytrofa, has shown strong sales and has the potential to be a blockbuster.
- Ascendis Pharma's TransCon PTH, a parathyroid hormone replacement therapy, is awaiting FDA approval and has the potential to capture a significant market share in the treatment of hypoparathyroidism.
Summary
Read the full article on Seeking Alpha
For further details see:
An Update On Ascendis Pharma's Path To Profitability